BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

14 articles for V Bordas

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.EBI
Novartis Institute For Biomedical Research
Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.EBI
Glaxosmithkline
Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identification.EBI
Glaxosmithkline
Process route of compound of formula (IV), crystal form and preparation method thereforBDB
Shandong Danhong Pharmaceutical Co.
HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOFBDB
Shanghai Hansoh Biomedical
MASP INHIBITORY COMPOUNDS AND USES THEREOFBDB
Bayer Aktiengesellschaft
Histone deacetylase inhibitors and compositions and methods of use thereofBDB
Chdi Foundation
Histone demethylase inhibitorsBDB
Celgene Quanticel Research
Cyclopropanamine compound and use thereofBDB
Takeda Pharmaceutical
Compounds and methods for inhibiting JAKBDB
Astrazeneca
Pyridine compounds and the users thereofBDB
Purdue Pharma
Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes.BDB
UniversitÉ
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.BDB
Upjohn
Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity.BDB
Boehringer Mannheim